Skip to main content
    P

    Pacira BioSciences, Inc. (PCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $36.48
    +0.02 (+0.05%)

    Market Cap: $1.46B

    Last updated: Nov 17, 2026 at 3:04 AM ET

    Pacira BioSciences, Inc. (PCRX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Pacira BioSciences (PCRX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Pacira BioSciences reported EPS of $0.46, below the $0.47 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +40.01%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.84
    Range$0.70 - $0.98
    11 analysts
    Revenue Consensus
    $204.69M
    Range$189.05M - $214.40M
    10 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.73
    Range$0.65 - $0.89
    4 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.81-9.0%
    60d ago$0.80-7.9%
    30d ago$0.77-4.9%
    7d ago$0.76-4.0%
    Current$0.73
    Revenue Consensus
    $181.51M
    Range$175.69M - $185.10M
    3 analysts

    Next Report

    PCRX has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 162.5% above the $0.32 reported for the quarter ended Dec 31, 2025.

    PCRX Earnings Call

    The latest PCRX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PCRX beat 26, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $176.65M, down 1.6% from $179.52M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.46$0.47N/A-2.13%Miss-34.3%91 up, 0 downNov 5, 2026$176.65M
    Jun 30, 2026$0.44$0.27N/A+62.96%Beat-40.5%61 up, 6 downAug 4, 2026$192.40M
    Mar 31, 2026$0.60$0.56$0.46 - $0.65+7.14%Beat-3.2%70 up, 1 downApr 30, 2026$177.38M
    Dec 31, 2025$0.32$0.60N/A-46.67%Miss-64.8%71 up, 1 downFeb 26, 2026$196.87M
    Sep 30, 2025$0.70$0.65$0.62 - $0.71+7.69%Beat-11.4%60 up, 1 downNov 6, 2025$179.52M
    Jun 30, 2025$0.74$0.71$0.64 - $0.81+4.23%Beat-16.9%61 up, 0 downAug 5, 2025$181.10M
    Mar 31, 2025$0.62$0.60$0.49 - $0.77+3.33%Beat0.0%72 up, 0 downMay 8, 2025$168.92M
    Dec 31, 2024$0.91$0.83$0.62 - $0.95+9.60%Beat+2.2%73 up, 0 downFeb 27, 2025$187.25M
    Sep 30, 2024$0.79$0.70$0.58 - $0.93+12.86%Beat+9.7%90 up, 0 downNov 6, 2024$168.57M
    Jun 30, 2024$0.89$0.70$0.53 - $0.83+27.14%Beat+14.1%92 up, 0 downJul 30, 2024$178.02M
    Mar 31, 2024$0.62$0.62$0.50 - $0.800.00%In line+17.0%90 up, 1 downMay 7, 2024$167.12M
    Dec 31, 2023$0.89$0.87$0.75 - $0.98+2.30%Beat+11.2%82 up, 0 downFeb 29, 2024$181.24M
    Sep 30, 2023$0.72$0.78$0.68 - $0.87-7.69%Miss+12.5%80 up, 1 downNov 2, 2023$163.93M
    Jun 30, 2023$0.78$0.76$0.48 - $0.87+2.63%Beat+52.9%80 up, 1 downAug 2, 2023$169.47M
    Mar 31, 2023$0.53$0.62$0.56 - $0.69-14.52%Miss-17.2%82 up, 0 downMay 3, 2023$160.34M
    Dec 31, 2022$0.80$0.83$0.70 - $0.98-3.61%Miss-17.5%90 up, 0 downFeb 28, 2023$838.78M
    Sep 30, 2022$0.64$0.76$0.50 - $0.88-15.79%Miss-11.1%110 up, 2 downNov 3, 2022$167.47M
    Jun 30, 2022$0.51$0.85$0.74 - $1.16-40.00%Miss-33.8%102 up, 0 downAug 3, 2022$169.41M
    Mar 31, 2022$0.64$0.83$0.56 - $1.09-22.89%Miss+20.8%112 up, 0 downMay 4, 2022$157.99M
    Dec 31, 2021$0.97$0.90$0.67 - $1.70+7.78%Beat+11.5%121 up, 0 downFeb 24, 2022$159.19M
    Sep 30, 2021$0.72$0.65N/A+10.77%Beat+5.9%122 up, 0 downNov 3, 2021$127.72M
    Jun 30, 2021$0.77$0.74$0.63 - $0.91+4.05%Beat+541.7%12N/AAug 3, 2021$135.59M
    Mar 31, 2021$0.53$0.63$0.41 - $0.91-15.87%Miss0.0%13N/AMay 4, 2021$119.03M
    Dec 31, 2020$0.87$0.81$0.62 - $0.97+7.41%Beat+55.4%15N/AFeb 25, 2021$130.97M
    Sep 30, 2020$0.68$0.65$0.42 - $0.74+4.62%Beat+41.7%14N/AOct 29, 2020$117.48M
    Jun 30, 2020$0.12$0.09-$0.21 - $0.35+33.33%Beat-70.7%14N/AAug 6, 2020$75.50M
    Mar 31, 2020$0.53$0.30$0.14 - $0.49+76.67%Beat+140.9%16N/AMay 7, 2020$105.68M
    Dec 31, 2019$0.56$0.44$0.28 - $0.55+27.27%Beat+19.1%14N/AFeb 20, 2020$122.42M
    Sep 30, 2019$0.48$0.33$0.24 - $0.42+45.45%Beat+54.8%15N/ANov 7, 2019$104.69M
    Jun 30, 2019$0.41$0.34$0.19 - $0.42+20.59%Beat+70.8%15N/AAug 8, 2019$102.60M
    Mar 31, 2019$0.22$0.26$0.13 - $0.43-15.38%Miss+1000.0%14N/AMay 2, 2019$91.31M
    Dec 31, 2018$0.47$0.28$0.04 - $0.45+67.86%Beat+23.7%15N/AFeb 28, 2019$95.11M
    Sep 30, 2018$0.31$0.08$0.01 - $0.13+287.50%Beat+181.8%15N/ANov 1, 2018$83.45M
    Jun 30, 2018$0.24$0.07-$0.03 - $0.20+242.86%BeatN/A18N/AAug 2, 2018$84.11M
    Mar 31, 2018$0.02$0.03-$0.13 - $0.17-33.33%MissN/A18N/AMay 3, 2018$74.61M
    Dec 31, 2017$0.38$0.10-$0.08 - $0.25+280.00%Beat+322.2%18N/AFeb 28, 2018$79.08M
    Sep 30, 2017$0.11-$0.07-$0.29 - $0.09+257.14%Beat-45.0%15N/ANov 8, 2017$67.33M
    Jun 30, 2017-$0.11-$0.05-$0.27 - $0.07-120.00%Miss-157.9%12N/AAug 2, 2017$70.93M
    Mar 31, 2017-$0.19-$0.04N/A-375.00%Miss-235.7%N/AN/AMay 4, 2017$69.28M
    Dec 31, 2016$0.09$0.01N/A+800.00%Beat-55.0%N/AN/AMar 1, 2017$72.90M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.38, down 25.9% from the year before. It was $0.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.38-25.9%
    Dec 31, 2024$3.21+9.9%
    Dec 31, 2023$2.92+12.7%
    Dec 31, 2022$2.59-13.4%
    Dec 31, 2021$2.99+35.9%
    Dec 31, 2020$2.20+31.7%
    Dec 31, 2019$1.67+60.6%
    Dec 31, 2018$1.04+447.4%
    Dec 31, 2017$0.19-69.4%
    Dec 31, 2016$0.62N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20264,89511
    2026Q1Mar 31, 20264,95211
    2025Q4Dec 31, 20256,10811
    2025Q3Sep 30, 20255,90210
    2025Q2Jun 30, 20255,76710
    2025Q1Mar 31, 20256,21111
    2024Q4Dec 31, 20246,13411
    2024Q3Sep 30, 20244,37310

    2026Q2 Earnings Call

    Opening remarks

    Susan Mesco Head of Investor Relations Thank you. Good afternoon, everyone. Welcome to today's conference call to discuss our Second Quarter of 2026 Financial Results. Joining me are Frank Lee, Chief Executive Officer, Brendan Teehan, Chief Commercial Officer, and Shawn Cross, Chief Financial Officer. Kristen Williams, Chief Administrative Officer and Secretary, Anthony Molloy, Chief Legal Officer, and Jonathan Slonin, Chief Medical Officer, are also here for today's question and answer session. Before we begin, let me remind you that this call will include forward-looking statements subject to the safe harbor provisions of federal securities laws. These statements represent our judgment as of today and may involve risks and uncertainties. This may cause our actual results, performance, or achievements to differ materially. For information concerning risk factors that could affect the company, please refer to our filings with the SEC or the Pacira website. Lastly, as a reminder, we will be discussing non-GAAP financial measures on today's call. A description of these metrics along with our reconciliation to GAAP can be found in the news release issued this afternoon. With that, I will now turn the call over to Frank Lee.

    Frank Lee Chief Executive Officer Thank you, Susan, and good afternoon to everyone joining today's call. On behalf of the remarkable team here at Pacira, I'm pleased to share our continued progress in executing our 5x30 strategy and transitioning into a more innovation-driven pharmaceutical company. Our second quarter performance reflects disciplined execution of our 5x30 strategy, translating into commercial momentum, strong cash generation, pipeline advancement, and high-caliber partnerships. Furthermore, our 5x30 progress was clearly recognized with a decisive shareholder vote for both our strategy and director nominees at our annual meeting in June. Notable second quarter accomplishments include revenues of more than $109 million, even as macroeconomic pressures weighed on certain elective procedures in the hospital setting. Adjusted EBITDA of nearly $50 million. Establishing a scalable, commercially viable, U.S.-based manufacturing process for PCRX-201, a testament to our team's clinical development and manufacturing capabilities. Opening enrollment in Part B of our Phase 2 ASCENT study for PCRX-201, completing enrollment in the iovera registrational study in spasticity, and completing the iovera divestiture on July 31st, and forming a partnership in spasticity with Zimmer Biomet. I'd like to thank the Pacira and Zimmer Biomet teams for working so collaboratively and efficiently over the past 30 days to close this transaction. I look forward to continued partnership with our Zimmer Biomet colleagues going forward. I'll begin with a high-level overview of EXPAREL, and then Brendan will cover additional commercial details shortly. EXPAREL continues to penetrate and gain share across all segments, despite softness in certain deferrable soft tissue procedures, which historically wax and wane with macroeconomic conditions.

    Frequently Asked Questions About PCRX

    When is Pacira BioSciences's next earnings date?

    Pacira BioSciences's next earnings report is expected for Feb 24, 2027.

    Did PCRX beat earnings estimates last quarter?

    No. Pacira BioSciences reported EPS of $0.46 for the quarter ended Sep 30, 2026, below the $0.47 estimate by 2.13%.

    What EPS do analysts expect from PCRX next quarter?

    The consensus EPS estimate for Pacira BioSciences for the quarter ending Dec 31, 2026 is $0.84 from 11 analysts, with estimates from $0.70 to $0.98.

    How often does PCRX beat earnings estimates?

    Pacira BioSciences beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +5.77%.